SCHEMBL2733976

SCHEMBL2733976

CC(C)c1nccc2c1[nH]c1ccccc12

nearest known ligand 0.65

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TDO2 P48775 8/20 0.65
KDM4E B2RXH2 4/20 0.65
MEN1 O00255 3/20 0.65
MAPT P10636 3/20 0.65
KMT2A Q03164 3/20 0.65
MAPK1 P28482 2/20 0.65
NPSR1 Q6W5P4 2/20 0.65
ALDH1A1 P00352 2/20 0.65
GABRP O00591 1/20 0.65
GABRD O14764 1/20 0.65
CYP1A2 P05177 1/20 0.65
CYP3A4 P08684 1/20 0.65
CYP2D6 P10635 1/20 0.65
GABRA1 P14867 1/20 0.65
HPGD P15428 1/20 0.65
TSHR P16473 1/20 0.65
GABRB1 P18505 1/20 0.65
GABRG2 P18507 1/20 0.65
NFKB1 P19838 1/20 0.65
MAOA P21397 1/20 0.65

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29756407 1.00 TDO2 (0.65) TDO2KDM4EMEN1MAPTKMT2A
SCHEMBL30763468 0.89 DYRK1A (0.63) TDO2KDM4EMEN1MAPTKMT2A
SCHEMBL10631483 0.89 DYRK1A (0.63) TDO2KDM4EMEN1MAPTKMT2A
SCHEMBL30763467 0.89 DYRK1A (0.63) TDO2KDM4EMEN1MAPTKMT2A
SCHEMBL30763469 0.89 DYRK1A (0.63) TDO2KDM4EMEN1MAPTKMT2A
SCHEMBL30763470 0.89 DYRK1A (0.63) TDO2KDM4EMEN1MAPTKMT2A
SCHEMBL28812452 0.84 TDO2 (0.58) TDO2KDM4EMEN1MAPTKMT2A
SCHEMBL29045951 0.80 PARP14 (0.54) TDO2KDM4EMEN1MAPTKMT2A
SCHEMBL29045946 0.80 PARP14 (0.54) TDO2KDM4EMEN1MAPTKMT2A
Harman SCHEMBL141723 0.79 MAOA (1.00) TDO2KDM4EMEN1MAPTKMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250333412-A1 SUBSTITUTED PYRIDO[3,4-B]INDOLES FOR THE TREATMENT OF CARTILAGE DISORDERS SANOFI SA (FR) 2025-10-30 US disclosed
US-12275733-B2 Substituted pyrido[3,4-b]indoles for the treatment of cartilage disorders SANOFI (FR) 2025-04-15 US disclosed
US-20240182469-A1 SUBSTITUTED PYRIDO[3,4-B]INDOLES FOR THE TREATMENT OF CARTILAGE DISORDERS SANOFI (FR) 2024-06-06 US disclosed
US-11827633-B2 Substituted pyrido[3,4-b]indoles for the treatment of cartilage disorders SANOFI (FR) 2023-11-28 US disclosed
CN-110382496-B Substituted pyrido [3,4-b ] indoles for the treatment of cartilage disorders 赛诺菲 2022-08-09 CN disclosed
US-11130755-B2 Substituted pyrido[3,4-b]indoles for the treatment of cartilage disorders SANOFI (FR) 2021-09-28 US disclosed
EP-3792262-A1 SUBSTITUTED PYRIDO[3,4-B]INDOLES FOR THE TREATMENT OF CARTILAGE DISORDERS SANOFI (FR) 2021-03-17 EP disclosed
EP-3535263-B1 SUBSTITUTED PYRIDO[3,4-B]INDOLES FOR THE TREATMENT OF CARTILAGE DISORDERS SANOFI SA (FR) 2020-09-30 EP disclosed
US-20200095242-A1 SUBSTITUTED PYRIDO[3,4-B]INDOLES FOR THE TREATMENT OF CARTILAGE DISORDERS SANOFI (FR) 2020-03-26 US disclosed
US-10590158-B2 Total synthesis of shishijimicin A and analogs thereof WILLIAM MARSH RICE UNIVERSITY (US) 2020-03-17 US disclosed
US-20160039845-A1 BIS-B-CARBOLINE COMPOUND AND PREPARATION METHOD, PHARMACEUTICAL COMPOSITION AND USE THEREOF XINJIANG HUASHIDAN PHARMACEUTICAL RESEARCH CO., LTD (CN) 2016-02-11 US disclosed
EP-2924042-A1 BIS- -CARBOLINE COMPOUND AND PREPARATION METHOD, PHARMACEUTICAL COMPOSITION AND USE THEREOF Xinjiang Huashidan Pharmaceutical Research Co., Ltd. (CN) 2015-09-30 EP disclosed
EP-2924042-A1 BIS- -CARBOLINE COMPOUND AND PREPARATION METHOD, PHARMACEUTICAL COMPOSITION AND USE THEREOF Xinjiang Huashidan Pharmaceutical Research Co., Ltd. (CN) 2015-09-30 EP disclosed
CN-104812761-A Bis-beta-carboline compound and preparation method, pharmaceutical composition and use thereof XINJIANG HUASHIDAN PHARMACEUTICAL RES CO LTD 2015-07-29 CN disclosed
CN-104755078-A Application of harmine derivatives in preparation of antimicrobial agents XINJIANG HUASHIDAN PHARMACEUTICAL RES CO LTD 2015-07-01 CN disclosed
US-20130274258-A1 CARBAZOLE AND CARBOLINE DERIVATIVES, AND PREPARATION AND THERAPEUTIC APPLICATIONS THEREOF PHILIP MORRIS PRODUCTS S.A. (CH) 2013-10-17 US disclosed
EP-2635575-A1 CARBAZOLE AND CARBOLINE DERIVATIVES, AND PREPARATION AND THERAPEUTIC APPLICATIONS THEREOF Philip Morris Products S.a.s. (CH) 2013-09-11 EP disclosed
CN-103070862-A Application of harmine derivative in preparation of antibacterial drugs XINJIANG HUASHIDAN PHARMACEUTICAL RES CO LTD 2013-05-01 CN disclosed
EP-2455378-A1 Carbazole and carboline derivatives, and preparation and therapeutic applications thereof Philip Morris Products S.A. (CH) 2012-05-23 EP disclosed
WO-2012059232-A1 CARBAZOLE AND CARBOLINE DERIVATIVES, AND PREPARATION AND THERAPEUTIC APPLICATIONS THEREOF PHILIP MORRIS PRODUCTS S.A (CH) 2012-05-10 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160039845-A1 BIS-B-CARBOLINE COMPOUND AND PREPARATION METHOD, PHARMACEUTICAL COMPOSITION AND USE THEREOF BRCA1, CA7, DCK TDO2 3232/4885KDM4E 3383/4885MEN1 123/4885
US-10590158-B2 Total synthesis of shishijimicin A and analogs thereof SYK, UGT1A7, FCGRT TDO2 2794/4885KDM4E 408/4885MEN1 3370/4885
US-11827633-B2 Substituted pyrido[3,4-b]indoles for the treatment of cartilage disorders COL2A1, IDO1, COL1A1 TDO2 89/4885KDM4E 706/4885MEN1 3788/4885
US-11130755-B2 Substituted pyrido[3,4-b]indoles for the treatment of cartilage disorders COL2A1, IDO1, COL1A1 TDO2 89/4885KDM4E 706/4885MEN1 3788/4885
US-20130274258-A1 CARBAZOLE AND CARBOLINE DERIVATIVES, AND PREPARATION AND THERAPEUTIC APPLICATIONS THEREOF CCNI, CCNY, CYCS TDO2 1026/4885KDM4E 2711/4885MEN1 775/4885
US-20200095242-A1 SUBSTITUTED PYRIDO[3,4-B]INDOLES FOR THE TREATMENT OF CARTILAGE DISORDERS COL2A1, IDO1, COL1A1 TDO2 89/4885KDM4E 706/4885MEN1 3788/4885
US-20240182469-A1 SUBSTITUTED PYRIDO[3,4-B]INDOLES FOR THE TREATMENT OF CARTILAGE DISORDERS COL2A1, IDO1, COL1A1 TDO2 89/4885KDM4E 706/4885MEN1 3788/4885
US-12275733-B2 Substituted pyrido[3,4-b]indoles for the treatment of cartilage disorders COL2A1, IDO1, COL1A1 TDO2 89/4885KDM4E 706/4885MEN1 3788/4885
US-20250333412-A1 SUBSTITUTED PYRIDO[3,4-B]INDOLES FOR THE TREATMENT OF CARTILAGE DISORDERS COL2A1, IDO1, COL1A1 TDO2 82/4885KDM4E 723/4885MEN1 3740/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.